Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine
Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine
复制标题
DOI：
10.1016/j.ejca.2005.04.028
复制
发表时间：
2005-08-01
影响因子：
8.4
通讯作者：
Gianni, L
中科院分区：
文献类型：
--
作者：
Bianchi, G;Vitali, G;Gianni, L
乙酰肉碱(ALC)可改善非肿瘤性神经病变。我们对25例在紫杉醇或顺铂治疗期间或停药后持续至少3个月的神经病变分级(CTC)为3级的患者进行了8周的口服ALC(1g，tid)检测。一位独立的神经科医生在ALC前后对患者进行了评估。除一名患者外，所有患者都报告症状缓解，只有两名患者描述了1级恶心。感觉神经病变分级改善15例(60%)，运动神经病变11例(79%)。包括神经生理指标在内的总神经病变评分(TNS)改善23例(92%)。分别检测22例和21例患者感觉波幅和传导速度(腓肠神经和腓肠神经)的改善。在ALC后13个月的中位数，13名可评估患者中有12名的症状持续改善。鉴于其在改善已建立的紫杉醇和顺铂神经病变方面的效果，我们推荐ALC检测在预防神经毒性化疗期间进展或恢复症状方面的作用。(C)2005爱思唯尔有限公司。保留所有权利。
Acetyl-L-carnitine (ALC) improves non-oncological neuropathies. We tested oral ALC (1 g tid) for 8 weeks in 25 patients with neuropathy grade >= 3 (common toxicity criteria-CTC) during paclitaxel or cisplatin therapy, or grade >= 2 persisting for at least three months after discontinuing the drugs. An independent neurologist assessed patients before and after ALC. All patients except one reported symptomatic relief, and only two described grade 1 nausea. The sensory neuropathy grade improved in 15 of 25 (60%), and motor neuropathy in 11 of 14 patients (79%). Total neuropathy score (TNS) that included neurophysiological measures improved in 23 (92%). Amelioration of sensory amplitude and conduction velocity (sural and peroneal nerves) was measured in 22 and 21 patients, respectively. Symptomatic improvement persisted in 12 of 13 evaluable patients at median 13 months after ALC. In view of its effect in improving established paclitaxel- and cisplatin-neuropathy, we recommend ALC testing in preventing progression or revert symptoms during neurotoxic chemotherapy. (C) 2005 Elsevier Ltd. All rights reserved.